Newly Diagnosed Multiple Myeloma Clinical Trials

44 clinical trials for Newly Diagnosed Multiple Myeloma across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT — RECRUITING · PHASE3
• 18F-Fluciclovine PET/CT in Multiple Myeloma — RECRUITING · PHASE2
• NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide — RECRUITING · PHASE3
• Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma — RECRUITING · PHASE1
• A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) — RECRUITING · PHASE3
• EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial — RECRUITING · PHASE2
• Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients — RECRUITING
• Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients — RECRUITING
• Biomarkers in Multiple Myeloma — RECRUITING · NA
• Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients — RECRUITING · PHASE2
• Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients — RECRUITING
• A randomised trial of Daratumumab to remove myeloma cells from blood stem cells before an autograft for patients with multiple myeloma — OTHER · PHASE3
• Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). — NOT_YET_RECRUITING · PHASE3
• A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel — TERMINATED · PHASE2
• A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen — NOT_YET_RECRUITING · PHASE4
• ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma — NOT_YET_RECRUITING · PHASE2
• GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D. — TERMINATED · PHASE3
• Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation — WITHDRAWN · PHASE2
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – MajesTEC-4 — TERMINATED · PHASE3
• Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma — NOT_YET_RECRUITING · PHASE1
• Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) — TERMINATED · PHASE3
• Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma — TERMINATED · PHASE2
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide - A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom) — TERMINATED · PHASE3
• Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM — ACTIVE_NOT_RECRUITING · PHASE2
• Phase II study of iberdomide (CC220) maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients — TERMINATED · PHASE2
• A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE — TERMINATED · PHASE2
• A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE — TERMINATED · PHASE2
• RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM — ACTIVE_NOT_RECRUITING · PHASE2
• Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma — NOT_YET_RECRUITING · PHASE3
• A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation — OTHER · PHASE2
• Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients — TERMINATED · PHASE2
• Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) — COMPLETED · PHASE2
• Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM — ACTIVE_NOT_RECRUITING · PHASE3
• Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients — WITHDRAWN · PHASE4
• Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma — OTHER
• Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM — OTHER · NA
• Multiple Myeloma and Exercise — COMPLETED · NA
• A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. — COMPLETED · PHASE3
• Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma — TERMINATED · PHASE3

Refine this search